Do all individuals with type 2 diabetes mellitus prefer decentralisation in clinical trials? Findings from a discrete choice experiment
Open Access
Abstract
Objectives: To explore differences in preferences for participation in trials with varying degrees of decentralisation among individuals with type 2 diabetes mellitus (T2DM) and to show how personal, disease specific, digital and trial experience factors influence these preferences as well as impact potential trial participation rates. Design: A discrete choice experiment was conducted, including 16 choice tasks, with each two trial options and an opt-out. Setting: Preference data was collected in the Netherlands between July 2023 and July 2024. Participants: A total of 276 individuals with T2DM aged ≥18 years took part in the study. Outcome measures: Trial options comprised six attributes: contact with the study team, activities to perform yourself, use of digital technologies, number of scheduled contacts, trial duration, safety and efficacy of the drug. Preference heterogeneity was explored using a latent class analysis. Results: Four classes were identified displaying differences in preferences for trial designs. Younger female participants were more likely to have a strong preference for decentralised trials in any form. Two different classes of elderly participants were identified: elderly males who were more likely to accept any trial design including decentralisation versus elderly who were more likely to be averse to participation in all trials. The latter class showed an increase in participation probability for a home-based trial including video consultation, but still was not very likely to join. Conclusions: Decentralisation in trials was overall preferred over site-based trials, but variation in preferences was identified and associated with age and gender. This may impact the choice for decentralisation in trials, especially since women and the elderly are often under-represented in trials. Understanding patient preferences may help to overcome participation challenges and to increase diversity in future trials.Keywords
Funding Information
- Innovative Medicines Initiative 2 Joint Undertaking (831458)
This publication has 90 references indexed in Scilit:
- Decentralized Clinical Trials as a New Paradigm of Trial Delivery to Improve Equity of AccessJAMA Oncology, 2024
- Enrollment of Older Patients, Women, and Racial and Ethnic Minority Individuals in Valvular Heart Disease Clinical TrialsJAMA Cardiology, 2023
- Underreporting and Underrepresentation of Race and Ethnicity in Head and Neck Cancer Trials, 2010-2020JAMA Otolaryngology–Head & Neck Surgery, 2022
- Analysis of Female Enrollment and Participant Sex by Burden of Disease in US Clinical Trials Between 2000 and 2020JAMA Network Open, 2021
- Trial characteristics associated with under‐enrolment of females in randomized controlled trials of heart failure with reduced ejection fraction: a systematic reviewEuropean Journal of Heart Failure, 2020
- Enrollment of Older Patients, Women, and Racial/Ethnic Minority Groups in Contemporary Acute Coronary Syndrome Clinical TrialsJAMA Cardiology, 2020
- Participation of Women and Older Participants in Randomized Clinical Trials of Lipid-Lowering TherapiesJAMA Network Open, 2020
- Decentralized Trials in the Age of Real‐World Evidence and Inclusivity in Clinical InvestigationsClinical Pharmacology & Therapeutics, 2019
- Barriers to recruiting ethnic minorities to mental health research: a systematic reviewInternational Journal of Methods in Psychiatric Research, 2014
- Effects coding in discrete choice experimentsHealth Economics, 2005